

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Guangzhou Innogen Pharmaceutical Group Co., Ltd.**

**廣州銀諾醫藥集團股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*

**(Stock Code: 2591)**

**CHANGE OF JOINT COMPANY SECRETARY; AGENT FOR SERVICE  
OF PROCESS AND AUTHORISED REPRESENTATIVE;  
AND  
WAIVER FROM STRICT COMPLIANCE  
WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

**CHANGE OF JOINT COMPANY SECRETARY, AGENT FOR SERVICE OF PROCESS  
AND AUTHORISED REPRESENTATIVE**

The board (the “**Board**”) of directors (the “**Directors**”) of Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the “**Company**”) hereby announces that Ms. Sze Suet Ling (施雪玲) (“**Ms. Sze**”) has resigned as (i) a joint company secretary of the Company (the “**Joint Company Secretary**”); (ii) the agent for service of process of the Company (collectively referred to as the “**Agent for Service of Process**”) for the acceptance of service of legal process on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Cap. 622 of the Laws of Hong Kong) and for the acceptance of service of legal process and notices on behalf of the Company in Hong Kong under Rule 19A.13(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) the authorised representative of the Company (the “**Authorised Representative**”) under to Rule 3.05 of the Listing Rules, due to personal career development reason with effect from 23 March 2026.

Ms. Sze has confirmed that she has no disagreement with the Board and there are no other matters in respect of her resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or the Stock Exchange. The Board is also not aware of other matters that need to be brought to the attention of the Shareholders and the Stock Exchange in connection with her resignation.

The Board would like to take this opportunity to express its gratitude for Ms. Sze’s valuable contribution to the Company during her tenure of office.

The Board is pleased to announce that Ms. Mak Po Man Cherie (“**Ms. Mak**”) has been appointed as (i) a Joint Company Secretary; (ii) the Agent for Service of Process; and (iii) Authorised Representative with effect from 23 March 2026. Ms. Yang Dongyan (楊東妍) (“**Ms. Yang**”) has been and will continue to be the other Joint Company Secretary. As a Joint Company Secretary, Ms. Mak will work closely with Ms. Yang and assist her in discharging her duties as the Joint Company Secretary and gaining relevant experience as required under Rule 3.28 of the Listing Rules.

The biographical details of Ms. Mak are set out below:

Ms. Mak, 51 years old, is the Vice President of SWCS Corporate Services Group (Hong Kong) Limited. She has worked for various professional firms and listed companies in Hong Kong, with over 20 years of experience in the fields of audit, accounting, corporate finance, compliance and corporate secretarial matters. Ms. Mak obtained a Master of Corporate Governance degree from The Hong Kong Polytechnic University in 2017. She was admitted as an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in 2017, a member of the Hong Kong Institute of Certified Public Accountants in 2003, and a fellow member of the Association of Chartered Certified Accountants in 2006.

The biographical details of Ms. Yang are set out below:

Ms. Yang Dongyan (楊東妍), aged 40, obtained a bachelor's degree in law from the East China University of Political Science and Law (華東政法大學) in 2008 and holds a Legal Professional Qualification Certificate (《法律職業資格證書》). Between August 2008 and April 2021, Ms. Yang held various roles at Shanghai Wyselead Law Firm (上海市匯理律師事務所), including as a lawyer between March 2011 and November 2020 and a partner between November 2020 and April 2021. Since April 2021, Ms. Yang has served as the legal director of the Group.

## **WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

Reference is made to the announcement of the Company dated 6 February 2026 in relation to the appointment of Ms. Yang as a Joint Company Secretary and the existing waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules granted by the Stock Exchange (the “**Existing Waiver**”) for a period of three years commencing from the date on which Ms. Yang was appointed as a Joint Company Secretary, i.e. 6 February 2026, to 5 February 2029 (the “**Waiver Period**”). Pursuant to the Existing Waiver, if Ms. Yang is no longer assisted by Ms. Sze during the Waiver Period, the Existing Waiver will be withdrawn immediately.

On the basis of the foregoing, the Company has applied for, and the Stock Exchange has granted, a new waiver (the “**New Waiver**”) from strict compliance with Rules 3.28 and 8.17 of the Listing Rules for the remaining Waiver Period (i.e. from the date of Ms. Mak's appointment as a Joint Company Secretary to 5 February 2029) (the “**Remaining Waiver Period**”), on the following conditions:

- (i) Ms. Yang must be assisted by Ms. Mak during the Remaining Waiver Period; and
- (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Ms. Yang, having had the benefit of Ms. Mak's assistance during the Remaining Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the New Waiver if the Company's situation changes.

The Board would like to take this opportunity to welcome Ms. Mak on her new appointment.

By order of the Board  
**Guangzhou Innogen Pharmaceutical Group Co., Ltd.**  
**Dr. WANG QINGHUA**  
*Chairman of the Board*

Shanghai, the People's Republic of China, 23 March 2026

*As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.*